Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis.

What It Covers

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this meta-analysis publication.

To explore the effect of short-acting growth hormone (GH) supplementation on bone age and growth rate of children with idiopathic short stature.

Weighted average difference (WMD) was calculated as the primary outcome to evaluate the effect of bone age and growth rate, and the WAD in adverse reactions was considered as the secondary outcome.

Who the Included Studies Covered

PubMed indexes the participants as children.

The authoritative databases such as PubMed, Medline, and Web of Science were extensively searched through the systematic and comprehensive literature retrieval strategy to compile the clinical research data on the treatment of idiopathic short stature with short-acting GH.

The study will be strictly screened to ensure that all enrolled research subjects are patients with idiopathic short stature, and the intervention method is defined as short-acting GH replacement therapy, and a reasonable control group is set, such as placebo treatment, to ensure the scientificity and comparability of research results.

How the Review Was Done

In this study, RevMan 5.3, a professional statistical software tool, was used to systematically perform the meta-analysis process.

What Was Measured

The subject headings attached to it are Human Growth Hormone, Growth Disorders, Body Height, Age Determination by Skeleton and Bone Development.

Author keywords: Bone age, Growth rate, Idiopathic short stature, Meta analysis and Short acting growth hormone.

What This Means in Plain Language

This is a meta-analysis of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (BMC pediatrics), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.